India: Compulsory License: The Most Happening Section Of The Patents Act, 1970

Last Updated: 15 October 2015
Article by Aayush Sharma

Most Read Contributor in India, September 2016

Case review: Lee Pharma vs. AstraZeneca’s ‘Saxagliptin’

In a year 2012, when Patent office issued India's first Compulsory license (CL) to Natco for Nexavar - sorafenib tosylate, Indian Patent law has gained lot of importance worldwide. Some countries are against the decision of granting of CL and some are in their favour. Pertinently, at the stage of grant of CL, India has faced lot of challenges among Pharma industry mainly on the issues of Intellectual Property. Grant of Natco compulsory license has brought a new hope in the Pharma industry and in the country where high prices of life saving drugs are just meant for few wealthy patients and not to the poor and needy.

The article will throw light on the laws prevailing with respect to the Compulsory license in Patents Act, 1970 and the reasons stated by the Controller in light of Section 84 of the Patent Act, 1970 for holding the CL application made by the Lee Pharma.


Compulsory licenses are generally defined as "authorizations permitting a third party to make, use, or sell a patented invention without the patent owner's consent." Under Indian Patent Act, 1970, the provision with regard to compulsory licensing is specifically given under Chapter XVI. The conditions which need to be fulfilled in order for a compulsory licence to be granted are laid down under Sections 84 and 92 of the Act. As per Section 84, any person who is interested or already the holder of the licence under the patent can make a request to the Controller for grant of Compulsory Licence on patent after three years from the date of grant of that patent on the existence of conditions mentioned in the Section 84 of the Patents Act, 1970. While granting the compulsory licence, the Patent office will take into account few measures such as the nature of the invention, any measures already taken by the patentees or any licencee to make full use of the invention, ability of the applicant to work the invention to the public advantage and time elapsed since the grant of the patent i.e. worked or not worked.


Section 841:

(1) At any time after the expiration of three years from the date of the grant of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds, namely:—

(a) that the reasonable requirements of the public with respect to the patented invention have not been satisfied, or

(b) that the patented invention is not available to the public at a reasonably affordable price, or

(c) that the patented invention is not worked in the territory of India.


After the successful grant of CL to Natco, many Pharma companies are now trying to grab the benefit of Compulsory licenses in order to make highly expensive drugs at a very low price and easily accessible to public.

Recently, Lee Pharma, a Hyderabad based Indian Pharma Company, filed a Compulsory Licensing (CL) Application for selling and manufacturing the compound on June 29, 2015 at the Patent office, Mumbai. The CL was filed against one of the patented drug 'Saxagliptin' protected under the Patent number 206543 in the name of AstraZeneca with tile as "A CYCLOPROPYL-FUSED PYRROLIDINE-BASED COMPOUND". As informed the 'Saxagliptin' was used for treating Type II Diabetes Mellitus.

Section 84(1) of Patents Act 1970 states that after the expiration of three years from the date of grant of patent any person may make an application for grant of compulsory licence on three grounds - the reasonable requirements of the public have not been satisfied or the patented invention is not available to the public at an affordable price or the patented invention is not worked in the territory of India3. According to the notice issued by the Patent office in August, 2015 the Controller has informed that the Lee Pharma failed to make out prima facie case for the CL application. Various reasons have been mentioned by the Controller where the Lee Pharma has failed to be as prima facie in the said CL application.

Earlier in the year 2014 Lee pharma has requested the AstraZeneca for license of the patented drug 'Saxagliptin'. The AstraZeneca then replied in response to the Lee pharma letter and provide the clarification for not giving any license along with the details of the availability of said drug. Further for not receiving the appropriate reply from the AstraZeneca, despite of the fact that AstraZeneca has send the email reply to Lee and Lee pharma was in fact that no reply has been received from AstraZeneca, the Lee pharma send many reminders to AstraZeneca and later approached to the Patent office for seeking the grant of compulsory license.

As per the Controller's decision in holding the application, the first request for license made by the Lee pharma to the AstraZeneca, was more than 13 months prior to the filing of the application at the Patent office. As per the time frame mentioned in section 84(4) of the Patents Act, 1970 is 06 months which has elapsed in the subject case without any efforts being successful. This is the first reason for holding the CL application of Lee pharma and denied the request.

As per the Section 84(1)(a) where reasonable requirements of the Public with respect of Patented invention has not been satisfied, in view of this, the Controller stated that the Prima facie case has not been made out by the Applicant to the effect that Lee pharma was unable to make out the reasonable requirements of the Public with respect of Patented invention. The Controller has noted the presence of equally efficacious DPP-4 inhibitors that can be substituted for Saxagliptin in treating Type II Diabetes Mellitus, and found that it was impossible for Lee to make assumptions about the demand for Saxagliptin without accounting for these substitutes4. This is the second reason for holding the CL application of Lee pharma and denied the request for CL.

Further the Lee pharma has also failed to Prima facie show that the patented invention is not available to the Public at a reasonable affordable price and thus no case has been made in such respect. This reason of Controller has been guided by the Bayer vs. UOI5 where the price difference quoted by the applicant and respondent was very high. i.e. Rs. 2,84,000 and Rs. 8,800 whereas in the present case, the price quoted by the Lee pharma was marginally cheaper than AstraZeneca's and thus the Controller has been unable to find that the patented product is not available at an affordable price as per Section 84(1)(b) of the Patents Act, 1970. Lastly as per Section 84(1) (c) of the Patents Act, the Lee pharma again failed to Prima facie show that the Patented invention is not worked in the territory of India and thus the reason for upheld the CL application for 'Saxagliptin' in India. In this section the Controller cited Bayer CL case where it was mentioned that local working does not entail local manufacturing in all cases. According to Controller, the patentee is only obligated to furnish reasons that make it prohibitive to manufacture the product locally, and that even this requirement holds particularly in those situations where the patentee possesses manufacturing capabilities in India. The Controller also held that in the absence of any data concerning AstraZeneca's local manufacturing capability provided by Lee pharma, they cannot accept that a prima facie case under this provision has been made out.


In reviewing the compulsory license case, there is one more section which is very important for the CL in India. Section 146(2) of the Patents Act, 1970 read with Rule 131 of the Patent Rules, 2003 compels every patentee and her licensee to make an annual disclosure as to how far and to what extent they have commercially worked their patent6. In this respect recently Delhi High Court issued notice to the Government of India in a PIL (Public Interest Litigation) filed by the petitioner7. This notice has been issued because most of the major pharma MNC's routinely violate patent working norms and the Indian Patent office has not taken any step in violating such norms to these companies. Before going further, there is a need to understand how section 146 related to the compulsory license. As per section 146(2) of the Patents Act, 1970 every patentee and her licensee has to make an annual disclosure as to how far and to what extent they have commercially worked their patent in India or abroad.


(1) The Controller may, at any time during the continuance of the patent, by notice in writing, require a patentee or a licensee, exclusive or otherwise, to furnish to him within two months from the date of such notice or within such further time as the Controller may allow, such information or such periodical statements as to the extent to which the patented invention has been commercially worked in India as may be specified in the notice.

(2)Without prejudice to the provisions of sub-section (1), every patentee and every licensee (whether exclusive or otherwise) shall furnish in such manner and form and at such intervals (not being less than six months) as may be prescribed statements as to the extent to which the patented invention has been worked on a commercial scale in India.

(3)The Controller may publish the information received by him under subsection (1) or sub-section (2) in such manner as may be prescribed.

In our Patent laws section 146 i.e. working statement plays an important role at the time of compulsory licensing cases. With the help of working statement [which are required to be filed before the expiration of 31st March of every year] the details provided by the Patentee or their licensee one can estimate whether the patentee has fulfilled the reasonable requirements of the public by interalia selling the patented product at an affordable price or at higher price violating the section 84 (1)(b) of the Patents Act. This information played a critical role in the Lee Pharma Ltd. Versus AstraZeneca and Bayer vs. Natco compulsory licensing dispute, where these details helped the Controller in getting the decision related to grant or rejection of Compulsory license when applied. In the first grant of CL application, Natco obtained the details from the working statement filed by the Bayer that its super expensive patented drug for kidney/liver cancer was reaching just about 2% of the patient population and sold at a very high price violating the section 84 norms of the Patents Act.

In this way, if the patentee fails to fulfil this important statutory information, the penalty in the form of compulsory licensing and revocation of Patent will come and this will take such companies in loss of Patent and also it is impossible to determine whether a patentee has satisfied the reasonable requirements of the public, an important precondition for compulsory licensing in India.


It is believed that this era will bring more challenges in terms of grant/ rejection of CL for more patented drugs. More rivalry is yet to be seen between Indian pharma giants and larger MNCs. The functioning of Indian Patent office in dealing with CL case will also bring more clarity about the future of CL in India and the rules prevailed such laws in India.

In the present case, it is to be understood that the Controller has not fully denied the CL application of Lee pharma rather the Controller has only inform the Lee pharma that they have not made out the prima facie case for the order under Section 84. As per the notice issued by the Controller, under Rule 97 (1), Lee pharma has one month from the date of notification to request for the hearing, if it wants to proceed with the application and if request for hearing is not made, Controller shall refuse the application.

Now it's time to watch how Lee Pharma prepare them for Grant of India's 2nd CL, the Controller's final decision in grant or rejection of such compulsory license and the impact of petition filed in respect of non submission of working statement details to those companies who are not following the proper submission of working disclosures.









The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.